Encapsulation of adenovirus serotype 5 in anionic lecithin liposomes using a bead-based immunoprecipitation technique enhances transfection efficiency.

Encapsulation of adenovirus serotype 5 in anionic lecithin liposomes using a bead-based immunoprecipitation technique enhances transfection efficiency.
复制标题

DOI:
10.1016/j.biomaterials.2014.08.010
复制
发表时间:
2014-11
期刊:
影响因子:
14
通讯作者:
Kummel, Andrew C.
Kummel, Andrew C.
中科院分区:
工程技术1区
文献类型:
--
作者:
Mendez, Natalie;Herrera, Vanessa;Zhang, Lingzhi;Hedjran, Farah;Feuer, Ralph;Blair, Sarah L.;Trogler, William C.;Reid, Tony R.;Kummel, Andrew C.

文献摘要

参考文献

被引文献

相似文献

溶瘤病毒(OV)构成了一类有前途的癌症治疗方法,它利用了已知在许多癌症中不受管制的经过验证的遗传途径。为了克服免疫反应并增强其治疗原发性和转移性肿瘤的潜在用途,开发了一种脂质体封装腺病毒的方法。通过在病毒衣壳周围自组装,将腺病毒封装在直径为 140-180 nm 的无毒阴离子卵磷脂-胆固醇-PEG 脂质体中。封装的病毒保留了感染癌细胞的能力。此外,免疫沉淀(IP)技术已被证明是一种快速有效的方法来提取非包膜病毒并使溶液中剩余的脂质体均质化。 IP 处理后,78% 的腺病毒空斑形成单位被封装并保留感染性。此外,与非封装病毒相比,封装病毒的转染效率提高了 4 倍。从溶液中提取非包膜病毒可以防止不利的体内免疫反应,并且可以增强多次给药的治疗效果。
Oncolytic viruses (OVs) constitute a promising class of cancer therapeutics which exploit validated genetic pathways known to be deregulated in many cancers. To overcome an immune response and to enhance its potential use to treat primary and metastatic tumors, a method for liposomal encapsulation of adenovirus has been developed. The encapsulation of adenovirus in non-toxic anionic lecithin-cholesterol-PEG liposomes ranging from 140–180nm in diameter have been prepared by self-assembly around the viral capsid. The encapsulated viruses retain their ability to infect cancer cells. Furthermore, an immunoprecipitation (IP) technique has shown to be a fast and effective method to extract non-encapsulated viruses and homogenize the liposomes remaining in solution. 78% of adenovirus plaque forming units were encapsulated and retained infectivity after IP processing. Additionally, encapsulated viruses have shown enhanced transfection efficiency up to 4× higher compared to non-encapsulated Ads. Extracting non-encapsulated viruses from solution may prevent an adverse in vivo immune response and may enhance treatment for multiple administrations.
DOI: 10.1016/j.nucmedbio.2003.07.003
发表时间: 2004-01-01
影响因子: 3.1
作者:
Chen, XY;Park, R;Conti, PS
通讯作者: Conti, PS
DOI: 10.1042/bj1860591
发表时间: 1980-01-01
影响因子: 4.1
作者:
KIRBY, C;CLARKE, J;GREGORIADIS, G
通讯作者: GREGORIADIS, G
DOI: 10.1016/0005-2736(91)90246-5
发表时间: 1991-07-01
期刊: BIOCHIMICA ET BIOPHYSICA ACTA
影响因子: --
作者:
ALLEN, TM;HANSEN, C;YAUYOUNG, A
通讯作者: YAUYOUNG, A
DOI: 10.1038/mt.2008.174
发表时间: 2008-11-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Corjon, Stephanie;Wortmann, Andreas;Kreppel, Florian
通讯作者: Kreppel, Florian
DOI: 10.1016/j.virol.2006.01.032
发表时间: 2006-06-05
期刊: VIROLOGY
影响因子: 3.7
作者:
Campos, Samuel K.;Barry, Michael A.
通讯作者: Barry, Michael A.